Pharmaceutical industry
The total control of drug development by pharmaceutical companies is both problematic and unsustainable. Pharmaceutical companies are often more concerned about profits than public health priorities or corporate accountability. As a result, key health priorities are neglected and people lack access to the medicine they need. Companies engage in harmful and unethical research practices, and irresponsible marketing practices. SOMO researches the policies and practices around pharmaceutical drug development, with a particular focus on the ethics of drug testing in low and middle income countries. Clinical trials in these countries often involve vulnerable people, raising serious ethical questions. We push pharmaceutical companies to act with due diligence in line with the UN Guiding Principles on Business and Human Rights in relation to peoples’ participation in clinical trials, as well as Post-Trial Access (PTA) to medicine.
Overview of articles
-
EU health data law rolls out the red carpet for Big TechPosted in category:Long read
Irene SchipperPublished on: -
Big Pharma raked in USD 90 billion in profits with COVID-19 vaccinesPosted in category:News
Esther de HaanPublished on: -
Pharma’s pandemic profits Published on:
Esther de HaanPosted in category:Publication
Esther de Haan
-
-
-
SOMO’s recommendation for HERA – the new European centre for cross-border health threatsPosted in category:Published on:Statement
-
Proposal European Parliament to make contracts between Europe and corona vaccine suppliers publicPosted in category:NewsPublished on: -
Recommendations on ODA eligibility of spending related to Covid-19 vaccinesPosted in category:Published on:Statement
-
Moderna vaccine profits channelled to tax havensPosted in category:News
Vincent KiezebrinkPublished on: -
-
Conditions placed on public funding of corona vaccines are hollowPosted in category:NewsPublished on: -
How can we make publicly funded corona vaccines accessible to all?Posted in category:Long read
Irene SchipperPublished on: -
-
Global vaccine scarcity unnecessary if pharma shares knowledgePosted in category:Published on:Statement
-
Transparency is a fundamental pillar for the success of the EU Vaccines StrategyPosted in category:Published on:Statement
-
-
Response of SOMO and Wemos to Government reaction on report ‘Overpriced’Posted in category:NewsPublished on: -
